This strategy was used to improve the delivery of HCQ and sonoactive chlorin e6 to glioma tumors using angiopep-2 peptide-modified liposomes that target low-density lipoprotein receptor-related protein 1 (LRP1) [47]. Here, LRP1 is linked to central nervous system cancer.